(Q39328604)

11 September 2017

1 reference

title

Antinuclear antibody testing - misunderstood or misbegotten? (English)

1 reference

11 September 2017

David S Pisetsky

1

1 reference

11 September 2017

language of work or name

English

0 references

publication date

25 May 2017

1 reference

Nature Reviews Rheumatology

11 September 2017

published in

1 reference

11 September 2017

volume

13

1 reference

11 September 2017

issue

8

1 reference

11 September 2017

page(s)

495-502

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2017.74

11 September 2017

exact match

0 references

cites work

International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Range of antinuclear antibodies in "healthy" individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

The clinical utility of a positive antinuclear antibody test result

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Latest update on the Ro/SS-A autoantibody system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Ribosomal P antibody: 30 years on the road

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

The translocation of nuclear molecules during inflammation and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Interferon-α induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Two major autoantibody clusters in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

The Clinical Features of Myositis-Associated Autoantibodies: a Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Antinuclear antibodies: Diagnostic significance and methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Choosing wisely: Review and commentary on anti-nuclear antibody (ANA) testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Autoantibody detection with indirect immunofluorescence on HEp-2 cells: starting serum dilutions for systemic rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Antinuclear antibody testing: discordance between commercial laboratories

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Establishment of HEp-2 cell preparation for automated analysis of ANA fluorescence pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Automated antinuclear immunofluorescence antibody screening: a comparative study of six computer-aided diagnostic systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

EUROPattern Suite technology for computer-aided immunofluorescence microscopy in autoantibody diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Detection of autoantibodies to ss‐a/ro by indirect immunofluorescence using a transfected and overexpressed human 60 kd ro autoantigen in hep‐2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Sensitivity of the HEp-2000 substrate for the detection of anti-SSA/Ro60 antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Prevalence and sociodemographic correlates of antinuclear antibodies in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Autoantibody profiling to follow evolution of lupus syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Autoantibodies and SLE: the threshold for disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

The Clinical Relevance of Anti-DFS70 Autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Measurement of anti-DFS70 antibodies in patients with ANA-associated autoimmune rheumatic diseases suspicion is cost-effective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

The Use of Poly-L-Lysine as a Capture Agent to Enhance the Detection of Antinuclear Antibodies by ELISA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

A simple, rapid ELISA method for the detection of DNA antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Autoantibody detection using multiplex technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

The uses and misuses of multiplex autoantibody assays in systemic autoimmune rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Protein arrays for autoantibody profiling and fine‐specificity mapping

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Anti-DNA antibodies--quintessential biomarkers of SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Immunologic factors and clinical activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Comparison of three anti-dsDNA assays: performance and correlation with systemic lupus erythematosus disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Four Anti-dsDNA Antibody Assays in Relation to Systemic Lupus Erythematosus Disease Specificity and Activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

ANA screening: an old test with new recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Rare autoantibodies to cellular antigens in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Mixed connective tissue disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Screening for IgG antinuclear autoantibodies by HEp-2 indirect fluorescent antibody assays and the need for standardization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Frequency of antinuclear antibodies in healthy children and adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Detection of antinuclear antibodies by solid-phase immunoassays and immunofluorescence analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Enzyme-linked immunosorbent assay for antibodies to native DNA in sera of patients with SLE

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

An improved ELISA for anti-native DNA by elimination of interference by anti-histone antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Microplate ELISA for detection of antibodies to DNA in patients with systemic lupus erythematosus: specificity and correlation with Farr radioimmunoassay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Simultaneous identification of various antinuclear antibodies using an automated multiparameter line immunoassay system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Evaluation of a novel line-blot immunoassay for the detection of antibodies to extractable nuclear antigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.74

Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests.

31 March 2020

1 reference

12 December 2020

Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent

1 reference

12 December 2020

A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories.

1 reference

12 December 2020

Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus

1 reference

12 December 2020

Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes.

1 reference

12 December 2020

Antidouble stranded DNA antibody assays in systemic lupus erythematosus: correlations of longitudinal antibody measurements

1 reference

12 December 2020

Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus

1 reference

12 December 2020

Comparison of antinuclear antibody testing methods: immunofluorescence assay versus enzyme immunoassay

1 reference

12 December 2020

Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology

1 reference

12 December 2020

Measurement of antinuclear antibodies by multiplex immunoassay: a prospective, multicenter clinical evaluation.

1 reference

12 December 2020

Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists

1 reference

12 December 2020

Relative value of commercial kits for ANA testing.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2017.74

1 reference

11 September 2017

1 reference